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The use of Chinese Hamster Ovary (CHO) cells for
transient gene expression is gaining importance steadily,
as it has been shown that both quality and quantity of
proteins derived from CHO cells differs from and can
even be superior to material derived from Human
Embryonic Kidney (HEK293) cells [1-4]. In order to
augment yields HEK cell lines have been genetically
modified, by e.g. stable integration of an expression cas-
sette coding for the Epstein-Barr Virus Nuclear Antigen
1 (EBNA1) in conjunction with expression plasmid vec-
tors containing the EBNA1 interaction site oriP. Here
we describe the generation of a CHO cell line stably
expressing the EBNA1 gene to enhance yields after large
scale transient transfection with polyethylenimine (PEI).
An expression plasmid featuring the EBNA1 gene was
transfected into an in-house available CHO wild type
cell line by nucleofection and several stable pools were
established by antibiotic selection. In a first approach,
133 clones were then isolated by limiting dilution clon-
ing and subsequently expanded for further analysis. The
approach aimed at identifying clones showing both the
presence of EBNA1 protein and enhanced yields after
PEI-mediated transient expression of a reporter protein
at the same time.
Cell lysates or nuclear and cytoplasmic protein
extracts from these clones were tested for presence of
EBNA1 protein by Western Blot. An in-licensed cell
line, CHO EBNALT85 (Icosagen AS, Tartu, Estonia)
expressing the full length EBNA1 gene, and the
HEK293-6E cell line (from the group of Y. Durocher,
NRC, Canada) expressing a truncated EBNA1 gene
served as positive controls. A number of commercially
available anti-EBNA1 antibodies were tested in Western
blotting, but most antibodies failed to detect the EBNA1
protein produced by these positive control cells. Only
one antibody (Antibody 1EB12, Santa Cruz Biotechnol-
ogy) was identified that detected the EBNA1 proteins in
both positive control cell lines.
However, by applying this antibody on the 133 gener-
ated clones it became obvious that in most of them the
EBNA1 protein appeared to be largely degraded.
The functionality of the EBNA1 protein in the cells
was probed by PEI-mediated transient transfection of
expression plasmids encoding the gene for the reporter
protein Secreted Alkaline Phosphatase (SeAP). SeAP
expression levels were compared with respect to pre-
sence or absence of the EBNA1 interaction sequence
oriP on the SeAP expression plasmid. Only one clone
showed a twofold enhanced production level of the
reporter protein compared to the non-engineered paren-
tal CHO cell line. However, in this specific clone no
EBNA1 protein could be detected by Western Blot, and
the enhanced expression level was independent from the
presence or absence of the oriP sequence on the SeAP
expression plasmid. We therefore conclude that this
clone does not possess a functional EBNA1 protein and
an EBNA1/oriP based enhancement of productivity. The
mechanism underlying the enhanced yield of the repor-
ter protein in this particular clone remains currently
elusive.
In an alternative approach flow cytometric cell sorting
was applied to generate CHO clones producing a func-
tional EBNA1 protein. Using the EBNA1 positive CHO
cell line CHO EBNALT85 it could be shown that
expressing eGFP from a transiently transfected expres-
sion plasmid with oriP sequence resulted in a 30- to 40-
fold increase of highly fluorescent cells in comparison to
an expression plasmid lacking the oriP sequence.
Thus, the already generated CHO pools stably trans-
fected with the EBNA1 gene were transiently super-
transfected with an eGFP expression plasmid containing
the oriP sequence. Highly fluorescent cells were
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any medium, provided the original work is properly cited.collected by cell sorting and expanded. Analysis by Wes-
tern Blot revealed that this sub-pool was enriched for
cells exhibiting the presence of a full length EBNA1 pro-
tein besides a major breakdown product. Transient
transfection of this sub-pool with SeAP expression vec-
tors led to the conclusion that the pool contained cells
with a functional EBNA1 protein capable of enhancing
SeAP yields in dependence on the presence of the oriP
sequence on the SeAP expression plasmid. Clones were
again generated from this sub-pool by limiting dilution
cloning and characterized in analogy to the first
approach. 9 out of 12 clones that were analyzed further
showed increased levels of reporter protein production
in dependence on the presence of the oriP element on
the expression plasmid. The series of clones exhibiting
highest expression levels will now be further evaluated
by expression of other protein candidates.
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